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Natural-food-based compounds show substantial promise for prevention and biotherapy of cancers including leukemia. In
general, their mechanism of action remains unclear, hampering rational use of these compounds. Herein we show that the
common dietary ﬂavonoid apigenin has anticancer activity, but also may decrease chemotherapy sensitivity, depending on the
cell type. We analyzed the molecular consequences of apigenin treatment in two types of leukemia, the myeloid and erythroid
subtypes. Apigenin blocked proliferation in both lineages through cell-cycle arrest in G2/M phase for myeloid HL60 and G0/G1
phase for erythroid TF1 cells. In both cell lines the JAK/STAT pathway was one of major targets of apigenin. Apigenin inhibited
PI3K/PKB pathway in HL60 and induced caspase-dependent apoptosis. In contrast, no apoptosis was detected in TF1 cells, but
initiation of autophagy was observed. The block in cell cycle and induction of autophagy observed in this erythroleukemia cell
line resulted in a reduced susceptibility toward the commonly used therapeutic agent vincristine. Thus, this study shows that
although apigenin is a potential chemopreventive agent due to the induction of leukemia cell-cycle arrest, caution in dietary
intake of apigenin should be taken during disease as it potentially interferes with cancer treatment.
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Apigenin (40,5,7-trihydroxyﬂavone), a common dietary ﬂavo-
noid abundantly present in fruits and vegetables, shows
promising biological effects such as prevention and therapy of
prostate cancer, suppression of tumorigenesis and angiogen-
esis in melanoma
1 and breast, skin, and colon carcinomas.
2 It
hasbeenshowntoexhibitantitumoraleffectsinleukemiacells
by induction of apoptosis through activation of caspases,
inhibition of fatty acid synthase and topoisomerase, and
modulationofBaxandBcl-2expression,
3andindeeddifferent
studies have reported antileukemic effects of apigenin.
4–7
Despite apigenin seems to be promising as a chemo-
preventive in leukemia, a rational design of trails investigating
its potential in this respect awaits further elucidation of its
molecular mode of action.
Studies in breast cancer cells have identiﬁed some of the
potential key protein kinases potentially responsible for
apigenin effects, in particular PI3K, PKB and ERK1/2, and
other upstream kinases involved in cancer development and
progression.
8 However, the effects of apigenin on these
kinases in leukemia have not been investigated.
The promise of apigenin now urgently calls for investiga-
tions as to its molecular mode of action in leukemia cellular
physiology. This consideration prompted us analyze the
molecular pathways activated by apigenin treatment on the
leukemic cell. To this end we established the induction of
cell-cycle arrest and cell death in two models of leukemic
disease, myeloid (HL60 cells) and erythroid (TF1 cells).
Results
Apigenin as a food-based antileukemia compound. Leukemia
cells and human peripheral blood lymphocytes were treated
with apigenin (Figure 1a) in concentrations up to 200mM,
for 24h. As shown in Figure 1b, apigenin caused a dose-
dependent reduction in viable leukemia cells. IC50 of apigenin
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In contrast, erythroleukemic cells were more resistant,
60±6% reduction of viability at 100mM was observed for
both K562 and TF1 cell lines. Importantly, no strong effect of
apigenin treatment was observed on normal human
peripheral blood lymphocytes, only 20% of cells were
sensitive to apigenin at the highest concentrations. These
results indicate that apigenin shows promise as a food-based
antileukemia compound.
Apigenin reduces survival due to cell-cycle arrest. As
HL60 and TF1 cells showed more sensitivity toward
apigenin, we continued our studies with these two cell
lines. We further investigated whether the reduced cell
numbers were a result of reduced cell cycling or increased
cell death, by following the number of viable cells over the
hours using vital stain Trypan blue. Apigenin 20, 30, and
40mM reduced to 60.4±11.7, 79.4±15.5, and 55.8±7%,
respectively, the number of viable HL60 cells (Figure 1c)
whereas the nontreated cells showed 170% of viability,
indicating that apigenin both stops cell proliferation
and drives HL60 cells into cell death. TF1 cells showed
175, 125, and 120% of viable cells at 24h treatment with 25,
50, and 100mM of apigenin, respectively, whereas
nontreated cells showed 225% viability (Figure 1d). Even
after 36h of 50 and 100mM apigenin, the cell viability
remained the same as control at 0h, and the baseline on
100% was not passed (Figure 1d) indicating that apigenin did
not induce cell death in TF1 cells, but blocked cell
proliferation.
Through analysis of DNA content by ﬂow cytometry, we
observed cell-cycle arrest of HL60 cells in G2/M phase by
apigenin (Figure 2a), as the number of cells in G2/M phase
increased dose dependently whereas the number of cells in S
Figure 1 Apigenin reduces cell viability of leukemia cells. (a) Molecular structure of apigenin. (b) Leukemia cells and human peripheral blood lymphocytes were treated
withapigeninfor24h.CellviabilitywasmeasuredbyMTTassayandcellviabilityofnontreatedcellswasconsideredas100%.(c)NumberofHL60viablecellsduringdifferent
times of treatment with apigenin. After HL60 cells treatment with apigenin for 5, 12, and 24h, the number of viable cells was quantiﬁed using Trypan blue. (d) Number of TF1
viable cells during different times of treatment with apigenin. TF1 cells were treated with apigenin for 18, 24, and 36h and using the Trypan blue the cell viable was quantiﬁed
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Cell Death and Diseasephase decreased. At 100mM apigenin, there were 58±8%
cells in G2 and M phases compared to 11.2±0.6% in
nontreated cells (Po0.05). The percentage of cells in S
phase dropped from 42.3±1.3% in nontreated cells to
21.4±2% in treated cells (Po0.01). This was in agreement
with an increase in apigenin-induced phosphorylation of Cdc2
at Tyr15 that results in inhibition of this kinase (Figure 2c).
Moreover, the expression of c-myc and p21 remained
unchanged (Figure 2c).
TF1 cells were arrested in the G0/G1 phase as shown in
Figure 2b. The number of cells in G0/G1 phase increased from
40.7±0.34% cell in untreated cells to 65.12±1.11% on
treatment with 50mM apigenin (Po0.01). The number of cells
inSphasewas44.6±3.6%innontreatedcellsanddecreased
to 18.6±0.9% in cells that received 50mM apigenin.
Corroboratingthese data,results shown in Figure 2drevealed
that apigenin led to a complete degradation or inhibition of
expression of CDK6, a protein essential for passage through
the G1/S phase restriction point. However, no changes were
observed in CDK4 protein levels. Hence apigenin is a potent
inhibitor of cell-cycle progression in a variety of model
systems of leukemia growth.
Downregulation of JAK/STAT pathway in both cells and
PI3K/PKB only in HL60 cells by apigenin. We decided to
establish the molecular details by which apigenin induces
cell-cycle arrest through the analysis of phosphorylation
status of some kinases and phosphatases involved in
leukemia cell proliferation and survival. Figure 3a shows
that treatment of HL60 cells with apigenin resulted in
downregulation of PI3K/PKB pathway, possibly due to a
decrease in PI3Kp85 subunit expression. We also observed
diminished phosphorylation of PKB Ser473 and of PDK-1
Ser241. In agreement with diminished PKB activity, we
observed diminished GSK3-b Ser9 phosphorylation.
Inhibition of the PI3K/PKB pathway can be a direct
consequence of activation of PTEN. As shown in
Figure 3c, apigenin treatment decreases phosphorylation of
PTEN at Ser380, leading to its activation, providing a
mechanistic explanation for this action of apigenin.
In contrast, no effect was observed on PI3K/PKB pathway
in TF1 cells treated with apigenin for 24h (Figure 3b).
Phosphorylation levels of PKB at Ser473 and phosphorylation
levels of GSK3-b remained unchanged. Unlike HL60 cells,
apigenin did not induce activation of PTEN in TF1 cells, which
Figure2 Apigenininducescell-cyclearrest.(a)NumberofHL60cellsindifferentphasesofcellcycle(G0/G1phase,SphaseandG2/M)asdeterminedbypropidiumiodide
stainingfollowedbyﬂowcytometry.(b)NumberofTF1cellsindifferentphasesofcellcycle.Cell-cycleanalysiswasperformedbymeasuringDNAcontentbypropidiumiodide
staining after treatment with speciﬁed concentrations of apigenin for 24h. (c) Expression of p21 and c-myc (middle and lower panels) and phosphorylation of CDC2 (upper
panel), key proteins in cell-cycle control in HL60 cells was determined using western blotting. (d) Expression CDK4 and 6 in TF1 cells by western blotting. Equal loading was
conﬁrmed by reprobing blots for b-actin
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Cell Death and Diseaseremained strongly phosphorylated at Ser380 (Figure 3c).
Thus, apigenin has differential effects depending on the cell
type involved.
To obtain more information about the action of apigenin in
cell survival, we analyzed MAPKp38, JAK2, and STAT3
and 5. In HL60 cells treated with apigenin an increase in
Figure 3 Analysis of cell proliferation pathways. Effect of apigenin treatment on key kinases involved in cell proliferation from HL60 (a) and TF1 (b) cells. (c) Effect of
apigenintreatmentonphosphatasesinvolvedinproliferationofHL60andTF1cells.Cellsweretreatedwithspeciﬁedconcentrationsofapigeninfor24handtheexpressionor
phosphorylation oftheproteinswasdeterminedusingwesternblotanalysis.Equalloadingwasconﬁrmedbyreprobingblotsfor b-actin.(d)Theactivityof immunoprecipitated
LMWPTPwasmeasuredafterapigenintreatmentofHL60andTF1cellsbyMalachitegreenassay.(e)Effectofapigenintreatmentonproteinsinvolvedincellsurvivalcontrol.
HL60 cells were treated with 50mM apigenin for 5, 12 and 24h; TF1 cells were treated with 100mM apigenin for 18, 24 and 36h; and the phosphorylation of the proteins was
determined by western blotting. Equal loading was conﬁrmed by reprobing them for b-actin
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Cell Death and Diseasephosphorylation of MAPKp38 was observed at Thr180/182,
essential for p38 catalytic action. However, in TF1 cells, the
p38 activity remained unchanged after apigenin treatment
(Figure 3a). JAK/STAT pathway was downregulated in both
cell lines, thus emerging as a general effect of apigenin in
leukemia. Apigenin led to decreased phosphorylation of JAK2
and STAT3 in both cell lines and STAT5 in TF1 cells (Figure
3a and b). The strong negative effect of apigenin on STAT3
phosphorylation in TF1 cells can be explained by increase of
expression (Figure 3c) and activity of LMWPTP (Figure 3d),
one of negative modulators of STATs,
9 as well as the strong
inhibition of SHP-2; LMWPTP activity was about 4-fold
(385±94%), 2-fold (198±28%), and 10-fold higher
(1083±47%) in the presence of 25, 50, or 100mM apigenin,
respectively.InHL60cells,theLMWPTPactivitywasinhibited
about 44, 37, and 36% at 20, 30, and 40mM apigenin,
respectively. Another activator of STATs, the Src protein
kinase, was also inhibited by apigenin treatment, showing
decrease of phosphorylation at Tyr416, an activation site, in
both cell lines, HL60 (Figure 3a) and TF1 (Figure 3b). Hence,
this general response toward apigenin across multiple types
of leukemia may be important for explaining its broad
antileukemic effects.
Both cell lines treated with apigenin showed a decrease of
phosphorylation of SHP-2 at activator residue Tyr542
(Figure 3c), which thus may also contribute to the growth
inhibition of leukemic cells observed.
TF1 cells show a constitutive activation of mTOR and,
consequently, activation of protein synthesis/cell growth
pathways (Figure 3e). In the presence of apigenin we
observed downregulation of p70S6K phosphorylation and
consequently, of S6 protein in TF1 cell. HL60 cells, however,
do not show constitutive activation of mTOR and p70S6K,
although apigenin decreased S6 protein phosphorylation.
Therefore, the functional importance of mTOR pathway
regulation in the apigenin response remains unclear.
Apigenin induces caspase-dependent apoptosis in
HL60, but not in TF1 cells. In HL60, we observed a
signiﬁcant increase in Annexin-V-positive cells, 31.9±4.1
and 48.13±2.6% for 50 and 100mM apigenin, respectively
(Figure 4a). Consistent with being more resistant to apigenin,
only moderate induction of apoptosis was observed at high
concentrations of apigenin in TF1 cells; at 100mM,
14.5±0.1% of cells stained Annexin V positive (Po0.002).
Figure 4 Analysis of apigenin-induced apoptosis in HL60 and TF1 cells. (a) Percentage of apoptotic cells after 24h treatment with apigenin (25, 50, and 100mM) was
determined using ﬂow cytometric analysis of Annexin V staining. (b) The effect of pan-caspase inhibitor Z-VADfmk on apigenin-induced cell death. Cells were pretreated with
50mM Z-VADfmkfor 1h before apigenintreatment.HL60 cellswere treatedwith 50mM apigeninandTF1 cellswere treatedwith 100mM apigeninfor 24h. (c and d) Effect of
PI3K inhibitor Ly294002 on apoptosis induction in HL60 (c) and TF1 (d) cells. Cells were pretreated with 5mM Ly294002 for 1h before 24h apigenin treatment. Afterwards,
cells were stained with propidium iodide (PI) and Annexin V. The combined Annexin-V-positive fractions were considered apoptotic (***Po0.001, **o0.01)
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Cell Death and DiseaseTo obtain more information about apigenin-induced apop-
tosis in HL60 and TF1 cells, we pretreated both lineages for
1h with 50mM of Z-VADfmk, a pan-caspase inhibitor, before
the 24h apigenin treatment. Figure 3b shows that pretreat-
ment of HL60 cells with Z-VADfmk reduced the number of
apoptotic cells 1.3-fold when compared to cells that received
apigenin only. No signiﬁcant difference in apoptosis induction
was observed in TF1 cells pretreated with Z-VADfmk
(Figure 4b), suggesting that apigenin induces caspase-
independent apoptosis in TF1 cells and caspase-dependent
apoptosis in HL60 cells.
To understand the role of the PI3K/PKB pathway in
apigenin-induced apoptosis, we treated cells for 2h with
5mM of LY294002, a PI3K inhibitor, before the 24h apigenin
treatment. As shown in Figure 4c, inhibition of PI3K with
LY294002 before apigenin treatment increased the number of
apoptotic HL60 cells 1.9-fold when compared with cells that
received apigenin only, showing the importance of PI3K/PKB
pathways in apoptosis resistance in this lineage. No statistic
difference in apoptosis induction was observed in TF1 that
received LY294002 before apigenin treatment comparing to
cells which received apigenin only (Figure 4c and d), showing
that TF1 cells are not dependent on PI3K/PKB pathway
activation for their resistance to apigenin-induced apoptosis.
Molecular mechanism of apoptosis induction by
apigenin. To further elucidate the apigenin-induced cell
death mechanisms in HL60 and TF1 cells, we analyzed the
Figure 5 Analysis of apoptosis pathway mechanism. (a) HL60 and TF1 cells were treated with apigenin for 24h. The expression of cleaved caspase-3, cleaved PARP,
and AIF was evaluated by immunoblotting. (b) Levels of full-length and cleaved caspase-8 (41, 43, and 18kDa) were determined. (c) Levels of cleaved and uncleaved
caspase-7 and cleaved caspase at different periods of apigenin treatment were investigated. HL60 cells were treated with 50mM apigenin for 5, 12 and 24h and TF1 cells
weretreatedwith 100mMapigeninfor18,24,and36h. Solublelysateswerematchedforprotein contentandanalyzedby westernblot analysis.Equalloadingwas conﬁrmed
by reprobing the blots with anti-b-actin antibodies
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Cell Death and Diseaselevels of cleaved caspase-3, -7, -8, and PARP. We observed
an increased dose- (Figure 5a) and time-dependent effect
(Figure 5c) on cleaved caspase-3 levels in HL60 cells. This
response was not observed in TF1 cells; only after treatment
with 100mM apigenin a small amount of cleaved caspase-3
(17kDa fragment) became apparent (Figure 5c). In HL60
cell, caspase-8 cleavage in apigenin-treated cells was
observed, indicating that the apoptosis extrinsic pathway
was also involved in apigenin cell death induction in this cell
line (Figure 5b). In HL60 the levels of full-length caspase-7
decreased when cells were treated with 50mM apigenin,
coinciding with increased presence of the 20kDa cleaved
caspase-7 fragment (Figure 5c).
In TF1 cells, neither cleavage of caspase-8 nor caspase-7
was observed (Figure 5a and b). Furthermore, the levels of
cleaved PARP remained unchanged in apigenin-treated cells.
We observed an increased of AIF levels at 25 and 50mM
apigenintreatmentinTF1cells(Figure5a),astrongindication
of caspase-independent apoptosis. These results emphasize
that despite the generalized leukemia growth inhibition
observed, the molecular consequences of apigenin treatment
show substantial context dependency.
Apigenin and autophagy. To obtain more insight into the
apigenin response in TF1 cells, we analyzed the apoptosis and
autophagy pathway activation in the time domain. For
apoptosis induction we used TNFa (10ng/ml) as a control.
TF1 cells were slightly induced to undergo apoptosis by TNFa,
as was deduced from cytokine-induced cleavage of caspase-7
to its 30kDa, but not 20kDa fragment and PARP cleavage.
Interestingly, TNFa also induced cleavage of LC3BI into
LC3BII after 24 and 36h of treatment and also induced high
expression of the autophagic proteins Atg5 and 12 (Figure 6b).
In addition, through electron microscopy (EM) we could
observe the signature double-membrane vacuoles, generally
accepted as strongly indicative for autophagy (Figure 6d and f).
In addition, TNFa activated P70S6K, which led to high
phosphorylation of S6 protein, indicative for protein synthesis
(Figure 6c), and apparently conﬁrmed by EM, as TNFa-treated
TF1 cells showed high numbers of ribosomes on endoplasmic
reticulum (ER) surface, indicative of high ER activity
(Figure 6e). Apigenin also induced autophagy in TF1 cells,
but through inhibition of mTOR and P70S6K. We observed a
strong reduction on phosphorylation of S6 protein. No changes
in beclin-1 levels were observed, however there was a strong
reduction of Atg5, 7, and 12 on TF1 cells treated with apigenin.
These data led us to conclude that autophagy is a dominant
response to apigenin treatment in at least some types of
leukemia.
Apigenin leads to apoptosis-like cell death in HL60 and
involves autophagy in TF1 as revealed by EM. Further
analysis of apigenin effects on HL60 and TF1 cells was
performed using EM, emphasizing the differential nature of
apigenin responses in leukemia (Figures 7 and 8). In HL60
cells treated with apigenin for 8h, we observed classical
apoptosis structures, chromatin condensation, and reduction
of cell volume (Figure 7b). At 24h of treatment most of cells
showed electron-dense cytoplasm with very condensed
nucleus and many of non-electron-dense vacuoles
(Figure 7c), and some necrotic cells were detected
(Figure 7c). In the electron-dense cytosol cell, we identiﬁed
double-membrane vacuoles, as shown in detail in Figure 7d.
TF1 cells showed morphological changes only after 36h of
treatment, where we could ﬁnd speckles in the nucleus
(arrows on the Figure 8c) and electron-dense mitochondria in
the cytoplasm (Figure 8c). In addition, a number of cells
showed non-electron-dense vacuoles and double-membrane
vacuoles, strong evidence of autophagy (Figure 8d). Thus,
there is not a common pathway leading to leukemia cell
death, despite the general antileukemic activity of apigenin
and experiments were initiated to explore the functional
consequences of this observation.
Apigenin diminishes the cytotoxic effect of the
chemotherapeutic vincristine in TF1 cells. The role of
autophagy in cells can be of dual consequence either it can
prolong cell survival in the absence of nutrients or it can
result in cell death. Induction of autophagy is often
associated with chemotherapy resistance. Indeed, TF1
cells pretreated with apigenin 24h prior of vincristine
showed diminishment of cytotoxic effect of chemotherapy
(Figure 8e and f). TF1 cells were treated with 100mM
apigenin for 24h, after the number of cells of treated and
nontreated cells was equalized, and cells were cultured with
or without vincristine treatment for an additional 24h. After
the treatment, the viable cells were counted using Trypan
blue (Figure 8e). In the absence of apigenin pretreatment,
vincristine reduced the number of viable to 39.2±6.1%,
compared to cells that did not receive vincristine (100%).
However, cells treated with apigenin before vincristine
treatment showed 147±7.3% viability, compared to the
cells that did not received vincristine (100%).
To obtain more data about the protective effect of apigenin
against vincristine, we further analyzed apoptosis induction.
TF1 cells were treated with apigenin for 24h, after which the
number of cells of treated and nontreated cultures was
equalized followed by the presence or absence of vincristine
treatment for an additional 24h. After the treatment, we
analyzedapoptosisinductionusingﬂowcytometricanalysisof
Annexin V binding. Cells that received neither apigenin nor
vincristine showed 10.7±0.007% Annexin-V-positive cells.
Vincristine treatment alone induced Annexin V staining
in 33.6±1.4% cells. Treatment of cells with apigenin alone
(for 48h) showed 22.34±0.4% Annexin-V-positive cells.
Strikingly, cells that were pretreated with apigenin followed
by vincristine treatment showed a reduction in Annexin-V-
positive cells when compared to vincristine treatment alone
(19.8±0.2%cells) (Figure 8f). Thus,we showedthatapigenin
protects TF1 against cell death induced by vincristine. We
conclude that although the effects of apigenin are generally
chemopreventive regarding leukemia, differential response
may include resistance to chemotherapy. Thus, use of such
food-based compound in an adjuvant setting when disease is
established might not be advisable.
Discussion
Our research group was interested in the possible beneﬁcial
biological effects of natural compounds and their derivatives
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Cell Death and Diseaseon malignant disease.
10–14 In this work, we explored the
effectsofapigenininleukemia,ﬂavonoidcommonlypresentin
human diet, which is emerging not only as potent cancer-
preventing agent, but also useful for adjuvant therapy.
11
Although the induction of apoptosis and cell-cycle arrest,
and inhibition of cancer-promoting signaling pathways,
certainly supports the chemopreventive action, especially as
untransformed lymphocytes do not seem to be really affected
by the compound, the observed interaction with therapeuti-
cally relevant drugs seems to rule this compound out for
adjuvant therapy as it may actually hamper treatment of
established disease.
Figure 6 Effect of apigenin treatment on key kinase molecules involved in the autophagy and apoptosis from TF1 cells. TF1 cells were treated with 10ng/ml TNFa or
100mMapigeninfor24and36h.(a)Levelsoffull-lengthandcleavedcaspase-7(30and20kDa),full-lengthandcleavedPARP.(b)Levelsautophagyproteinsbeclin-1,LC3B,
Atg5, 7, and 12. (c) Analysis of P70S6K/S6 pathway by western blotting. The expression or phosphorylation of the proteins was determined by western blot analysis. Equal
loadingwasconﬁrmedbyreprobingthemforb-actin.(d)ElectronmicroscopyofTF1cellstreatedwithTNFafor24h,detailofdouble-membranevacuoleinformation(original
magniﬁcation,  4500). (e) Detail of endoplasmic reticulum, showing intense protein synthesis (original magniﬁcation,  10000). (f) Detail of double-membrane vacuole
(original magniﬁcation,  10000)
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Cell Death and DiseaseIn HL60 cells, apigenin induced cell-cycle arrest in G2/M,
whereas TF1 cells were arrested in the G0/G1 phase. The
control of cell cycle is mediated by many protein complexes,
such as CDK and cyclins. Cdc2, normally driving cells into
mitosis, is the ultimate target of pathways that mediate rapid
arrest in G2, in response to DNA damage.
15 CDK6 forms a
complex with cyclin-D and targets the retinoblastoma protein,
allowing passage through the G1/S phase restriction point.
16
Many studies have reported that apigenin blocks cell cycle in
cancer cells,
17,18 however, depending on the cell type,
apigenin can arrest the cell cycle in different phases, for
example, it can lead G2/M arrest in colon carcinoma,
2 breast
cancer and pancreatic cancer cells.
19 Nevertheless, in human
prostate cancer, LNCap and PC3 cells, apigenin induced cell-
cycle arrest in G0/G1.
20 The results of this study extend these
observations that, depending on the cyclins affected, even in
the leukemic compartment responses may be substantially
different. The outcome of cell-cycle arrest may depend on the
phase in which the cell is arrested. Numerous studies,
including those using dietary compounds, have linked G2/M
arrest with subsequent apoptosis,
21,22 as was observed
for HL60 cells in our study. In contrast, G0/G1 arrest is seen
on reduction of mTOR activity,
23 and has been associated
with induction of autophagy,
24 reminiscent of apigenin effects
in TF1 cells in this study. p70S6K/S6 signaling has been
implicated in inhibition of autophagy,
25 and inactivation of the
mTOR signaling pathway is a prominent consequence of
PTEN activation.
26 In this study, although apigenin was not
able to activate PTEN in TF1 cells, mTOR was strongly
downregulated by apigenin. Thus, this ﬂavonoid may be an
attractive therapeutic agent for treating tumors carrying
inactivated PTEN. Studies with cancer stem cells have shown
that inhibition of mTOR pathways by rapamycin can block the
generation or maintenance of leukemia-initiating cells in the
PTEN-deﬁcient mice.
27
The role of autophagy in cell survival is a dual one; it can
either help cells to survive during stress or end in apoptosis in
the absence of cell rescue.
28 The autophagic characteristics
Figure 7 Electron microscopy of HL60 cells treated with apigenin for different time points. (a) Control cells, without treatment (original magniﬁcation,  3000). (b) Cells
treatedwithapigeninfor8h,showingclassicalapoptoticcells(condensedchromatin,reductionofcellsize,andnovacuoles);cellswithdensemitochondriaandnocondensed
chromatin and cells with size reduction, many vacuoles and no condensed chromatin (original magniﬁcation,  3000). (c) HL60 cell treated for 24h (original magniﬁcation,
 3000), showing necrotic cells and cells with many vacuoles. (d) Cells treated for 24h with apigenin, showing cells with dense chromatin, many vacuoles and double
membrane, detail in high magniﬁcation (original magniﬁcation,  20000) of vacuoles with cytosol content
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Cell Death and Diseaseobserved in HL60 cells suggest that the latter predominates in
this cell type following exposure to apigenin, whereas in TF1
cells autophagy is not followed by apoptosis, in apparent
agreement with the therapy-resistant phenotype of these
cells. Only after 36h of stringent apigenin treatment did a
small fraction of TF1 cells show signs of (a caspase-
independent form of) apoptosis. Interestingly, although show-
ing hallmarks of apoptosis on TNFa treatment, for example,
cleavage of PARP and caspase activation, EM analysis of
TNFa-treated cells showed characteristics of autophagy,
conﬁrmed by high levels of sentinel autophagic proteins
beclin-1, LC3BII, and Atg5, 7 and 12. In addition, TNFa
induced activation of the p70S6K/S6 pathway, indicating that
the induction of autophagy in TNFa-treated cells is induced by
high expression of autophagic genes related to vacuoles,
rather as of inhibition of P70S6K/S6 pathway.
Flavonoids have the potential to bind to the ATP-binding
sitesofalargenumberofproteinsduetotheirsimilaritytoATP
structure, which makes ﬂavonoids competitive inhibitors of
protein kinases.
29 Apigenin had already been reported to be a
competitive inhibitor of protein tyrosine kinases.
30 In this work
we clearly observed that apigenin inhibited PKB/PI3K path-
way in HL60 cells, through activation of PTEN and down-
regulation of PDK-1 and PI3K. Unlike HL60, TF1 showed no
changes in PI3K/PKB pathway under apigenin treatment.
Furthermore, MAPKp38 was activated in HL60 cells treated
with apigenin, but not in TF1 cells. Recently, it has been
suggested that p38 and JNK may be involved in the apoptotic
process by repression of ERK pathways.
31 Thus, the
differential effects of apigenin observed on leukemia cell
cycle are reﬂected by differential effects on kinase activities.
Interestingly, the only common target of apigenin in both
types of leukemia was the c-Src/JAK/STAT pathway, which
constitutes a major mediator of cytokine activity. Constitu-
tively active JAK2 proteins are associated with myelo-
proliferative disorders, acute lymphoblastic leukemia, acute
myeloid leukemia and acute megakaryoblastic leukemia,
and inhibition of STAT3 leads to increased apoptosis,
decreased proliferation, and decreased tumor size.
32
JAK/STAT pathway is regulated by SHP-2, which can
stabilize JAK2 protein or induce Src kinase activation.
Constitutive activation of SHP-2 in mice cooperates with
progression of myeloproliferative disorders.
33 In this work we
observed that apigenin downregulated SHP-2 and thereby
JAK2, which led to a decreased phosphorylation and activation
of STAT3 and 5. This effect was more apparent in TF1 cells,
which can be explained by the increased level and activity of
LMWPTP, another JAK/STAT downregulator, in this cell line.
FurtherexperimentationshouldrevealwhethertheJAK/STAT
signaling cassette is really the principal target for apigenin
effect in cancer in general.
Because apigenin induced cell-cycle arrest and autophagy
in TF1 cells, we hypothesized that apigenin could inhibit the
action of chemotherapeutic agents against leukemic cells.
One of the most common chemotherapeutics is vincristine,
and indeed on apigenin treatment, cells became more
Figure 8 Electron microscopy of TF1 cells treated with apigenin for different time points. (a) Control cells, without treatment (original magniﬁcation,  3000). (b) Cells
treated with apigenin for 24h show little morphological difference from nontreated cells (original magniﬁcation,  3000). (c) TF1 cells treated for 36h (original magniﬁcation,
 3000)presentdensemitochondria,partlycondensedchromatin,andspeckles(arrows)(originalmagniﬁcation,  3000).(d)Detailofvacuoleswithdoublemembraneinan
authophagic cell (original magniﬁcation,  20000). (e) Number of viable TF1 cells after vincristine treatment with or without apigenin pretreatment. TF1 cells were treated or
not treated with 100mM apigenin for 24h, after which cell numbers were normalized and cultured for another 24h with or without 2mM vincristine. The number of viable cell
was determined using Trypan blue. (f) Determination of percentage of apoptotic TF1 cells by ﬂow cytometric analysis of Annexin V staining. Cells were treated or not treated
with apigenin for 24h, after which cell numbers were normalized and cells were cultured for another 24h with or without 2mM vincristine
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tubulin dimers, inhibiting the formation of microtubules.
Disruption of the microtubules arrests mitosis in metaphase,
therefore, apigenin-induced blockage of TF1 cells in G0/G1
phase might enable these cells to escape the action of
vincristine. This action of apigenin clearly disqualiﬁes this
compound for adjuvant strategies once disease is estab-
lished, at least in relation to vincristine. However, it is
important to mention that when we combined apigenin with
imatinib or mitoxantrone no difference was observed (unpub-
lished data). Therefore, this observation reinforces our
hypothesis that the undesirable action of apigenin in the
presence of vincristine might be related to the action
mechanism of chemotherapeutics.
In conclusion, apigenin is a potential chemopreventive and
chemotherapeutic agent in leukemia due to the stimulation on
signaling pathways that provoke inhibition of cell proliferation
and cell-cycle arrest of fast-cycling cells. This work empha-
sizes the importance of a deep analysis of molecular
mechanism and biochemical details modiﬁed by a natural
compound with clinically useful properties. Extreme care
regarding consumption of such apigenin-like compounds
during chemotherapy must be exercised to prevent compro-
mising clinical success, and trails using such compound
should not be frivolously initiated. However, the possibility of
using apigenin as a model for drug design should not be
discarded.
Materials and Methods
Cell lines and reagents. HL60, K562, and TF1 cells were purchased from
ATCC (Rockville, MD, USA). Apigenin was from Sigma-Aldrich (Zwijndrecht, The
Netherlands). Polyclonal antibodies against AIF, p-PKB (Ser473), p-cdc2 (Thr15),
CDK4, CDK6, cleaved caspase-3, cleaved PARP, caspase-8, caspase-7, c-myc,
p-GSK-3b (Ser9), p-PI3K p85, p-PDK (Ser241), p-JAK2 (Tyr1007/1008), p-Src
(Tyr416), p-STAT3 (Tyr705), p-STAT5 (Tyr-694), p-p38 (Tyr108/182), p-SHP-2
(Tyr542), p-PTEN (Ser380), p-mTOR (Ser2448), p-p70S6K (Thr389), p-S6
(Ser235/236), Beclin-1, LC3BI/II, Atg5, Atg7, Atg12, anti-rabbit and anti-mouse
peroxidase-conjugated antibodies were from Cell Signaling Technology (Beverly,
MA, USA). p21 and TNFR1 antibodies were from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Antibody against LMWPTP was purchased from Abcam
(Zwijndrecht, The Netherlands). Apigenin and vincristine were purchased from
Sigma-Aldrich. Caspase inhibitor Z-VADfmk and apoptosis kit detection (Annexin
V-FITC and propidium iodide (PI)) were from BD Biosciences (San Diego, CA,
USA). The PI3K inhibitor LY294002 was from Alexis (La ¨ufelingen, Switzerland) and
TNFa was from Biovision Inc. (Mountain View, CA, USA)
Cell culture. Leukemia cells were cultured in RPMI 1640 containing 100U/ml
penicillin, 100mg/ml streptomycin, and 10% fetal bovine serum, at 371Ci na5 %
CO2humidiﬁedatmosphere.ForTF1cells,5ng/mlGM-CSFwasaddedto medium.
Human lymphocytes were obtained from healthy volunteers and isolated by
density through Ficoll Paque gradient. Mononuclear cells were harvested and
cultured in RPMI 1640 containing 100U/ml penicillin, 100mg/ml streptomycin, 10%
fetal bovine serum, and concanavalin A (5mg/ml) for 48h when the treatment was
carried out.
MTTassay. CellviabilitywasassessedbyMTTreductionassayasdescribedby
Mosmann.
34 Nontreated cells were taken as 100% of viability and IC50 values were
determined from three independent experiments.
Westernblotting. Cellswerelysed incelllysisbuffer(50mMTris-HCl(pH7.4)
containing 1% Tween 20, 0.25% sodium deoxycholate, 150mM NaCl, 1mM EGTA,
1mM o-vanadate, 1mM sodium ﬂuoride, 1mg/ml aprotinin, 10mg/ml leupeptin, and
1mM PMSF). After 15min of centrifugation the cleared lysates were
immunoprecipitated and resolved by reduced SDS-polyacrylamide gel
electrophoresis, the blots were incubated with the indicated antibodies and the
bands were visualized with ECL.
PTP activity. Cells were lysed in cell lysis buffer (20mM HEPES (pH 7.7),
2.5mM MgCl2, 0.1mM EDTA, 1% NP-40, 1mM 4-(2-aminoethyl)benzenesulfonyl
ﬂuoride hydrochloride, 1mM DTT, 10mg/ml aprotinin, and 10mg/ml leupeptin).
After 15min of centrifugation, the cleared lysates were immunoprecipitated with
GammaBind G Sepharose (GE Healthcare, Hoevelaken, The Netherlands) and the
phosphatase activity was determined using the PTP no radioactive assay kit from
Sigma.
Flow cytometry for apoptosis analysis. To perform the Annexin and PI
assays,theFITCAnnexinVApoptosisDetectionKitII fromBDPharmingen(Breda,
The Netherlands) was used. Brieﬂy, control and apigenin-treated cells were
collected, washed twice in cold PBS, resuspended in binding buffer (provided in the
kit), and stained with Annexin V FITC and PI.
Flow cytometry for cell-cycle analysis. After treatment with apigenin,
cells were spun down, washedwith PBS, andresuspendedin work solution(0.96g/
ml sodium citrate, 1mg/ml ribonuclease A, 0.02mg/ml PI, 0.01% Triton X-100).
After incubation in the dark for 60min at room temperature, the samples were
analyzed using FACSCalibur ﬂow cytometer (BD Biosciences).
Electron microscopy. HL60 and TF1 treated or nontreated with apigenin for
different periods were washed in RPMI, pelleted, and subsequently ﬁxed in 2%
glutaraldehyde in 0.1M phosphate buffer for 24h at 41C. Cells were dehydrated,
osmicated, and embedded in Epon812 according to routine procedures.
33 Semithin
sections (1–0.5mm) were examined by electron microscope (Philips 201; Philips,
Eindhoven, the Netherlands).
Statistical analysis. All experiments were performed in triplicate and the
results shown in the graphs represent the means and standard errors. Cell viability
data were expressed as the means±standard errors of three independent
experiments carried out in triplicates. Data from each assay were statistically
analyzedbyANOVA.DifferenceswereconsideredsigniﬁcantwhentheP-valuewas
o0.05. Western blotting analyses represent three independent experiments.
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